• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Eur Acad Dermatol Venereol . Herpes Zoster Viral (HZV) infection after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: a case series

tetano

tetano

Editor, Senior Moderator
J Eur Acad Dermatol Venereol


. 2021 Oct 4.
doi: 10.1111/jdv.17720. Online ahead of print.
Herpes Zoster Viral (HZV) infection after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: a case series


Dimitra Koumaki[SUP] 1 [/SUP], Sabine-Elke Krueger-Krasagakis[SUP] 1 [/SUP], Marios Papadakis[SUP] 2 [/SUP], Alexander Katoulis[SUP] 3 [/SUP], Vasiliki Koumaki[SUP] 4 [/SUP], George Evangelou[SUP] 1 [/SUP], Maria Stefanidou[SUP] 1 [/SUP], Dimitris Mylonakis[SUP] 1 [/SUP], Kyriaki Zografaki[SUP] 1 [/SUP], Konstantinos Krasagakis[SUP] 1 [/SUP]



Affiliations

Abstract

We report the first cases of Varicella Zoster Viral (VZV) infection after AZD1222 and BNT162b2 COVID-19 mRNA vaccines in Greece. As the World Health Organization ( WHO) declared the coronavirus disease-2019 (COVID-19) as a pandemic, the production for a safe and effective vaccine COVID-19 became a global priority. [SUP]1[/SUP] In December 2020, the European Medicines Agency (EMA) first approved the BNT162b2 (Pfizer-BioNTech COVID-19 mRNA) vaccine and the AZD1222 (Oxford/AstraZeneca COVID-19) vaccine. [SUP]2[/SUP].

Keywords: COVID-19; herpes zoster; vaccine.
 
You must log in or register to reply here.
Back
Top Bottom